Literature DB >> 15913737

Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies.

Qing-Yu He1, Yuan Zhou, Esther Wong, Thomas G Ehlen, Nelly Auersperg, Jen-Fu Chiu, Alice S T Wong.   

Abstract

OBJECTIVE: To study the pattern of protein expression associated with a predisposition to develop ovarian cancer.
METHODS: Prophylactic oophorectomy is used to prevent ovarian carcinoma in high-risk populations who have a strong family history of breast/ovarian cancer. In ovarian specimens of these women, the ovarian surface epithelium (OSE), which is tissue of origin of epithelial ovarian cancer, often shows altered morphology, growth patterns and differentiation features that are believed to be preneoplastic. This study has used a proteomic approach, based on two-dimensional gel electrophoresis and mass spectrometry, to compare the protein profiles of OSE from women with a history of familial ovarian cancer (FH-OSE), i.e., at least two first-degree relatives with such cancer and/or testing positive for BRCA1 mutations, to those without such history (NFH-OSE).
RESULTS: Of >1500 protein spots, there were 8 proteins whose levels were significantly altered in FH-OSE. Three were known ovarian tumor associated proteins, others were novel changes. A number of the alterations seen were accompanied with protein modifications and have not been previously reported. There was a predominance of sequences related to the stress response pathway. Differential expression of selected genes was confirmed by Western blotting and real-time reverse transcription polymerase chain reaction.
CONCLUSIONS: Our findings define the OSE phenotype of women at a high risk of developing ovarian cancer. Protein alterations seen in these tissues may represent an early, irreversible, non-mutational step in ovarian epithelial neoplastic progression and may be potential early and sensitive markers for the evaluation of cancer risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15913737     DOI: 10.1016/j.ygyno.2005.04.002

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  Novel surgical approaches for sampling the ovarian surface epithelium and proximal fluid proteome.

Authors:  Bunja Rungruang; Brian L Hood; Mai Sun; Ebony Hoskins; Thomas P Conrads; Kristin K Zorn
Journal:  J Proteome Res       Date:  2010-10-15       Impact factor: 4.466

2.  Measuring the intra-individual variability of the plasma proteome in the chicken model of spontaneous ovarian adenocarcinoma.

Authors:  Adam M Hawkridge; Rebecca B Wysocky; James N Petitte; Kenneth E Anderson; Paul E Mozdziak; Oscar J Fletcher; Jonathan M Horowitz; David C Muddiman
Journal:  Anal Bioanal Chem       Date:  2010-07-17       Impact factor: 4.142

3.  AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma.

Authors:  Fan Yang; Xiaoqing Guo; Gong Yang; Daniel G Rosen; Jinsong Liu
Journal:  Mod Pathol       Date:  2011-03-25       Impact factor: 7.842

4.  Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients.

Authors:  Francis Jacob; Kristjan Ukegjini; Sheri Nixdorf; Caroline E Ford; Jake Olivier; Rosmarie Caduff; James P Scurry; Rea Guertler; Daniela Hornung; Renato Mueller; Daniel A Fink; Neville F Hacker; Viola A Heinzelmann-Schwarz
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

5.  A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants.

Authors:  Alexander Gusev; Kate Lawrenson; Xianzhi Lin; Paulo C Lyra; Siddhartha Kar; Kevin C Vavra; Felipe Segato; Marcos A S Fonseca; Janet M Lee; Tanya Pejovic; Gang Liu; Beth Y Karlan; Matthew L Freedman; Houtan Noushmehr; Alvaro N Monteiro; Paul D P Pharoah; Bogdan Pasaniuc; Simon A Gayther
Journal:  Nat Genet       Date:  2019-05-01       Impact factor: 38.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.